logo

For the Inventor, By the Inventor

Heidelberg, Germany

Martina Benesova

This inventor holds 9 USPTO granted patents and 9 published patent applications and 4 EPO patents. Top assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitat Heidelberg, Ruprecht-Karls-Universitaet Heidelberg. Active years: 2018-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Martina Benesova. Retrieved from https://idiyas.com/inventor/martina-benesova

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.0

ph-index = 5

Forward Citations = 50(Granted Patents)


Location History:

  • Heidelberg, DE (2018 - 2024)
  • Neckarsteinach, DE (2020 - 2024)

Company Filing History:

goldMedal7 out of 159 
 
Deutsches Krebsforschungszentrum
 patents
silverMedal4 out of 64 
 
Ruprecht-Karls-Universitat Heidelberg
 patents
bronzeMedal3 out of 23 
 
Ruprecht-Karls-Universitaet Heidelberg
 patents
4. 2 out of 3,975 
 
Novartis Ag
 patents
where one patent can have more than one assignee

Years Active: 2018-2024

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents
1. 12054458 - F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer (2024-08-06),
2. 11951190 - Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer (2024-04-09),
3. 11931430 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer (2024-03-19),
4. 11638765 - Double-labeled probe for molecular imaging and use thereof (2023-05-02),
5. 11045564 - Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer (2021-06-29),
6. 10815200 - 18F—tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer (2020-10-27),
7. 10471160 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer (2019-11-12),
8. 10398791 - Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer (2019-09-03),
9. 10016519 - 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer (2018-07-10),

I specialize in the sphere of innovations, inventions, inventors, patent attorneys, assignees, and patents. If you have any questions related to these topics, feel free to ask.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…